Core Viewpoint - Medtronic (MDT) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, thus affecting stock prices [4]. Business Improvement Indicators - The upgrade in Medtronic's rating suggests an improvement in the company's underlying business, which is expected to be reflected in a higher stock price as investors respond positively to this trend [5][10]. - Medtronic is projected to earn $5.65 per share for the fiscal year ending April 2026, with a 0% year-over-year change, but the Zacks Consensus Estimate has increased by 0.5% over the past three months, indicating a positive revision trend [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Medtronic's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Investors with an interest in Medical - Products stocks have likely encountered both Medtronic (MDT) and EssilorLuxottica Unsponsored ADR (ESLOY) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strat ...

Core Insights - Medtronic plc (MDT) has received FDA approval for the Hugo robotic-assisted surgery (RAS) system, enhancing urologic surgical procedures and providing a versatile platform for minimally invasive care [1][9]. Company Developments - The Hugo RAS system builds on Medtronic's existing surgical offerings, including the Touch Surgery ecosystem, to create a connected operating room environment [2]. - Following the announcement on December 3, MDT shares increased by 0.02%, closing at $101.99, indicating a positive market reaction [3]. - Medtronic's current market capitalization stands at $130.73 billion, with an earnings yield of 5.5%, significantly higher than the industry average of 0.1% [4]. Product Features - The Hugo RAS system features a modular design that allows for flexible deployment across various care settings, enhancing utilization and customization for surgeons [5]. - The system includes an open surgeon console that improves situational awareness, reduces physical strain, and offers better training opportunities for surgical teams [5][6]. - It integrates with the Touch Surgery ecosystem, providing pre-operative training, remote tele-proctoring, and AI-driven post-operative insights, making Medtronic the only company to support all surgical modalities [6]. Market Potential - The global urology robotic surgery market is valued at $2 billion in 2024, with a projected CAGR of 8.7% through 2033, driven by the demand for minimally invasive surgeries [10]. - Medtronic plans to expand the Hugo RAS system's applications in the U.S. to include general and gynecologic surgical procedures following its initial urology clearance [7]. Stock Performance - Over the past six months, MDT shares have increased by 16.6%, outperforming the industry, which saw a decline of 1.3% [12].

Core Insights - Medtronic plc's board of directors approved a cash dividend of $0.71 per ordinary share for the third quarter of fiscal year 2026, consistent with a previous increase announced in May 2025 [1] - The company has a strong history of dividend payments, having increased its annual dividend for 48 consecutive years, and is part of the S&P 500 Dividend Aristocrats index [1] - The dividend will be payable on January 16, 2026, to shareholders of record as of December 26, 2025 [1] Company Overview - Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company focused on addressing significant health challenges through innovative solutions [2] - The company's mission is to alleviate pain, restore health, and extend life, supported by a workforce of over 95,000 employees across more than 150 countries [2] - Medtronic's technologies and therapies address 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems [2]

Core Insights - Medtronic has shown a significant rebound in performance, with a 30% increase in stock value this year, following a period of slow revenue growth and macroeconomic challenges [1] - The company reported strong quarterly results for fiscal 2026's second quarter, with revenue rising 6.6% year over year to $9 billion and adjusted earnings per share increasing 8% to $1.36, surpassing analyst expectations [2] Revenue Growth Drivers - A major growth driver for Medtronic is its Pulse Field Ablation (PFA) franchise, which treats atrial fibrillation, contributing to a 10.8% year-over-year increase in cardiovascular revenue to $3.4 billion, marking the fastest growth rate in over a decade for this segment [3][4] - Medtronic is gaining market share in the PFA niche and anticipates continued traction, which is expected to support steady top-line growth over the next 12 months [5] Strategic Business Moves - The company plans to spin off its diabetes care unit, which has been underperforming compared to competitors and has weak margins, accounting for only 4% of operating profits despite generating 8% of revenue in fiscal 2025 [6][7] - Medtronic is nearing clearance for its Hugo robotic-assisted surgery system, which has shown promise in clinical trials and is expected to be a significant growth area, despite competition from Intuitive Surgical [8] - The company is also expanding the Hugo system's indications, which is anticipated to increase demand and sales growth within this unit [9] Future Outlook - Following the positive quarterly results, Medtronic has raised its guidance for fiscal 2026, indicating strong short-term prospects [11] - The company is expected to benefit from long-term trends such as an aging population and ongoing product innovations, which should lead to competitive returns for patient investors [12] - Medtronic has a strong dividend history, having increased payouts for 48 consecutive years, positioning it as a reliable investment for dividend-seeking shareholders [13][14]

Financial Data and Key Metrics Changes - The company reported a delay in FDA approval by approximately one month due to a government shutdown, but European approval was achieved on time, and the paradigm study commenced largely as scheduled [46][47] - The cost structures are expected to reflect the scale-up into the study and the pathway to commercialization, with increased investments in R&D and manufacturing [47][48] - Access to capital has improved significantly with the company's data, transitioning from a penny dreadful to a legitimate multi-billion dollar product [48][52] Business Line Data and Key Metrics Changes - The company is focused on scaling up manufacturing and ensuring high-quality product delivery, with recent facility expansions tripling capacity [15][16] - The ADAPT process is highlighted for its unique anti-calcific response and improved patient outcomes, which is critical for clinical trials and production [12][13] Market Data and Key Metrics Changes - The company has seen a significant increase in liquidity, up 1,000%, following its listing on Nasdaq, which has improved access to capital [58] - The share price has been volatile, influenced by broader market trends, particularly in the MedTech sector, which has faced challenges [59][60] Company Strategy and Development Direction - The company aims to lead in the TAVR space by focusing on innovation and quality, with a commitment to patient outcomes and a strong corporate culture [4][5][6] - The management emphasizes the importance of quality and manufacturing processes to support the investment thesis and ensure successful commercialization [43][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's future, highlighting the importance of resilience and vision in navigating the complex healthcare landscape [7] - The company is positioned to lead the market, with competitors following its advancements in addressing aortic stenosis [44][45] Other Important Information - The company has expanded its distribution center significantly, preparing for increased volume in the upcoming months [33] - The leadership team includes experienced professionals from major global companies, enhancing the company's operational capabilities [43] Q&A Session Summary Question: What are the key milestones that support the investment thesis? - The integration of a team of leaders and experienced physicians has been crucial in achieving milestones, ensuring that the product meets market needs [76] Question: How does the company differentiate itself from competitors? - The company focuses on fundamentally different approaches to product development, aiming for significant improvements rather than incremental changes [70][71]

Annual Meeting December 2025 For personal use only NASDAQ: AVR | ASX: AVR Disclaimer Forward-Looking Statements This presentation (including oral commentary that accompanies this presentation) contains forward-looking statements, including statements related to our business, products and clinical trials and studies. Any statements about our expectations, beliefs, plans, predictions, forecasts, objectives, assumptions, or future events or performance are not historical facts and may be forward-looking. In so ...

Core Insights - Medtronic has received FDA clearance for its Hugo robotic-assisted surgery (RAS) system for urologic procedures, enhancing options for hospitals and surgeons in the U.S. [1] - The Hugo RAS system aims to address challenges in robotic surgery capacity and access, providing a versatile platform for minimally invasive care [1] Group 1: Product Features - The Hugo RAS system features a modular design that allows robotic arms to be easily moved and shared across different care settings, maximizing utilization and providing flexibility for surgeons [1] - It integrates with the Touch Surgery ecosystem, offering pre-operative training tools, remote tele-proctoring, and AI-powered post-operative insights, facilitating continuous improvement in surgical practices [1] - Medtronic is the only company that meets surgeon needs across all surgical modalities, providing access to world-class robotic training and trusted technologies [1] Group 2: Market Impact - The Hugo RAS system is indicated for minimally invasive urologic procedures such as prostatectomy, nephrectomy, and cystectomy, which account for approximately 230,000 surgeries annually in the U.S. [1] - The system has been utilized in tens of thousands of surgeries across more than 30 countries, indicating its global acceptance and potential for expansion in the U.S. [1] - Medtronic plans to extend the Hugo RAS system's applications to additional surgical specialties, including general and gynecologic procedures, following its initial urology clearance [1]

Summary of Orchestra BioMed Holdings FY Conference Call Company Overview - **Company**: Orchestra BioMed Holdings (NasdaqGM:OBIO) - **Focus**: Development of innovative medical technologies, particularly in the cardiovascular space, with two lead programs: AVIM therapy and Virtue Key Financial Developments - **Capital Raise**: Approximately $150 million raised since early August, comprising: - **Public Equity Offering**: Approximately $118 million from three transactions, including a strategic investment from Medtronic of around $12 million and a $20 million commitment in a novel debt structure [7][8] - **Strategic Partnership with Ligand**: $35 million committed for royalty interests in AVIM and Virtue [9][10] - **Relationship with Terumo**: $30 million brought in through a revised agreement [11][12] AVIM Therapy Insights - **Therapy Description**: AVIM therapy is designed for treating hypertensive heart disease via a pacemaker, with a revenue-sharing model with Medtronic [8] - **Clinical Trials**: Anticipated completion of the AVIM study in approximately seven months, with potential data release by late next year or early the following year [17][18] - **Efficacy Metrics**: Focus on reducing systolic blood pressure, with previous studies showing significant reductions [19][20] - **Patient Population**: Targeting older patients with isolated systolic hypertension, a demographic that is currently underserved [29][30] Market Opportunity - **Hypertension Market Size**: Estimated 1.2 billion patients globally, with 120 million in the U.S. alone [28] - **Pacemaker Market**: Over 1.1 million pacemakers implanted annually, with a significant percentage of these patients having high blood pressure [33][34] - **Medtronic's Market Position**: Medtronic holds approximately 50% market share in cardiac pacing therapies, providing a strong platform for AVIM therapy [32] Virtue Program Insights - **Drug Selection**: Sirolimus chosen over paclitaxel for its superior efficacy and safety profile in drug-eluting stents [37] - **Delivery Mechanism**: Innovative delivery system designed to optimize drug uptake and minimize procedural challenges [39] - **Clinical Results**: Early clinical results for Virtue show promise, with expectations to demonstrate superiority in pivotal studies [39] Strategic Partnerships - **Medtronic**: A key strategic partner for AVIM therapy, providing both investment and commercialization support [8][14] - **Ligand**: Their involvement reflects confidence in Orchestra BioMed's business model and potential for long-term success [15][16] Conclusion - **Future Outlook**: The company is positioned for significant growth with its innovative therapies and strong partnerships, particularly in the hypertension market, which presents a substantial opportunity for both AVIM and Virtue programs [34][35]

Core Insights - Medtronic plc has initiated the U.S. commercial rollout of the MiniMed 780G system integrated with Abbott's Instinct sensor, marking a significant advancement in diabetes management technology [1][8] - The MiniMed 780G system has received multiple regulatory approvals, including CE Mark for expanded indications and U.S. FDA approval for adults with type 2 diabetes, enhancing its market potential [2][4] - The global diabetes devices market is valued at $30.31 billion in 2023 and is expected to grow at a CAGR of 7.5% through 2030, driven by increasing diabetes prevalence and technological advancements [9] Company Developments - The MiniMed 780G system automatically adjusts insulin every five minutes based on real-time glucose readings, simplifying diabetes management [4][5] - The integration of Abbott's Instinct sensor, which features advanced continuous glucose monitoring technology, enhances the MiniMed 780G's capabilities [4][6] - Medtronic's Diabetes business is experiencing a strong innovation cycle, with recent product launches expanding its sensor portfolio [2][6] Financial Performance - Medtronic's market capitalization stands at $132.48 billion, with fiscal 2026 EPS expected to grow by 2.9% over 2025 [3] - The company reported worldwide revenues of $8.961 billion for fiscal 2026 second-quarter, reflecting a 6.6% year-over-year increase, with the Diabetes business growing particularly strong in international markets [10] - Year-to-date, Medtronic's shares have increased by 27.8%, outperforming the industry growth of 3.9% [11]